Dysregulation of oxylipins metabolism has been implicated in both Alzheimer’s disease and type 2 diabetes (Morris et al., 2019), suggesting that oxylipin mechanism in GPR39 KO mice might be shared with VCI pathophysiology. Here, GPR39 is linked to Alzheimer disease.